1130 Group offers research & development of ancillary inhalation devices with focus on 420 & 710 formulations. Having a long-history with US medical devices, and engineering, the design began in NY which led to the US Patented "flagship" technology. 1130 developed a new starting point for end-users to consume extracts. In turn, this secures a strong platform to expand our inhalation methods while current industry standards are destined to ALL fail future FDA compliance and regulation.
Established in 2021
After conception in 2015, the Clarity Pen® system began initial prototyping and engagement with industry leaders. Quickly identifying multiple-deficits surrounding inhalation devices it was clear to our pioneers that this "better process / technique" would sustain future regulation & compliance the maturing industry was missing. This clear vision of the deficits surrounding the efficacy of inhalation medicaments, lead to an investment in a CE, RoHS electronics company in Shenzhen, China, and begun to fight for the Global patent protection which the US was later received Aug 2021.
It was clear to us from the start that "air activated" cartridges which contained filaments inside the pre-filled hardware expedited the degradation of the extracts well before the end-user had a chance to benefit from it. This obvious shortfall leads us to the second deficit, transportation. How do environmental conditions play into the efficacy of the pre-filled extracts? Oxidation & outside contaminants are seen immediately after leaving the lab and begin its journey through ground and air transportation, left to sit on the shelf to later be acquired.